Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CNCR Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisDividendHeadlinesHoldingsRatingsShort InterestTrends About Range Cancer Therapeutics ETF (NASDAQ:CNCR) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get CNCR alerts:Sign Up Key Stats Today's Range$11.87▼$12.2150-Day Range$27.45▼$32.2552-Week Range$25.99▼$35.82Volume2,507 shsAverage Volume6,668 shsMarket Capitalization$14.27 millionAssets Under Management$9.94 millionDividend Yield2.40%Net Expense Ratio0.79%Aggregate RatingModerate Buy ETF OverviewThe Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.Read More… Range Cancer Therapeutics ETF ExpensesTypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.79%0.57%0.55%0.50%0.52%Other Expenses0.00%0.30%0.49%0.41%0.53%Total Expense0.79%0.70%0.71%0.64%0.71%Fee Waiver0.00%-0.45%-0.51%-0.31%-0.56%Net Expense0.79%0.61%0.61%0.57%0.59% Receive CNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address CNCR ETF News HeadlinesTango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge FundsNovember 23, 2024 | msn.comBuy Rating Affirmed for TScan Therapeutics Amid Positive Developments in TCR-T Cell Therapy SpaceOctober 12, 2024 | markets.businessinsider.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.December 21, 2024 | Crypto Swap Profits (Ad)Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC SubpopulationSeptember 9, 2024 | seekingalpha.comRange Oncology Therapeutics Index ETF (CNCR)August 15, 2024 | finance.yahoo.comTango Therapeutics Shuts Early-Stage Cancer Study Due To Liver ToxicityMay 23, 2024 | msn.comSee More Headlines CNCR ETF - Frequently Asked Questions What other stocks do shareholders of Range Cancer Therapeutics ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Range Cancer Therapeutics ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF). Fund Details IssuerExchange Traded Concepts Fund NameRange Cancer Therapeutics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CNCR Inception Date10/13/2015 Fund ManagerDenise M. Krisko WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkRange Cancer Therapeutics Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings76 Fund Statistics Assets Under Management$9.94 million Average Daily Volume$3,212.70 Discount/Premium0.06% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorExchange Traded Concepts, LLC CustodianU.S. Bank, N.A. DistributorQuasar Distributors, LLC Transfer AgentU.S. Bank, N.A. TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest3,900 shs Miscellaneous Outstanding Shares1,180,000Beta1.36 Creation Unit50,000 Creation Fee$150.00 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report Top 10 CNCR HoldingsRecursion Pharmaceuticals (NASDAQ:RXRX)Holding Weight: 3.02%Monte Rosa Therapeutics (NASDAQ:GLUE)Holding Weight: 2.60%ImmunityBio (NASDAQ:IBRX)Holding Weight: 2.03%Ginkgo Bioworks (NYSE:DNA)Holding Weight: 1.97%Replimune Group (NASDAQ:REPL)Holding Weight: 1.90%Exelixis (NASDAQ:EXEL)Holding Weight: 1.87%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 1.83%Xencor (NASDAQ:XNCR)Holding Weight: 1.71%Bristol-Myers Squibb (NYSE:BMY)Holding Weight: 1.67%SpringWorks Therapeutics (NASDAQ:SWTX)Holding Weight: 1.64%Full Holdings DetailsCNCR Sector ExposureCNCR Industry Exposure This page (NASDAQ:CNCR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.